The evaluation the effect of nanocurcommin in people living with HIV
Phase 1
- Conditions
- The effect of nanocurrcomin in HIV treatment.
- Registration Number
- IRCT20210216050373N4
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
people with positive test ( PCR)
people with positive test ( Elisa)
Exclusion Criteria
Patient with hepatitis B
Patient with hepatitis C
Pregnancy
Breastfeeding
Alcohol and Drug use
Use of Growth Hormone (at least 30 days before the study)
Use of Immunosuppressive drugs
Use of Testosterone and Anabolic Steroids (at least 30 days before the study)
Under Chemotherapy with Interferon or Radiotherapy
Patients with Undetectable viral loads
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Counting CD4 test. Timepoint: 30 days after first use. Method of measurement: with Flow cytometry instrument.;Viral load test. Timepoint: 30 days after first use. Method of measurement: ?????? PCR.
- Secondary Outcome Measures
Name Time Method